Proto-Oncogene Proteins c-met
"Proto-Oncogene Proteins c-met" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations in the c-met proto-oncogene are associated with papillary renal carcinoma and other neoplasia.
| Descriptor ID |
D019859
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.075 D12.776.543.750.630.186 D12.776.543.750.750.400.100 D12.776.624.664.700.186
|
| Concept/Terms |
Proto-Oncogene Proteins c-met- Proto-Oncogene Proteins c-met
- Proto Oncogene Proteins c met
- MET Receptor Tyrosine Kinase
- c-Met Receptor Tyrosine Kinase
- c Met Receptor Tyrosine Kinase
- Receptor, Hepatocyte Growth Factor
- met Proto-Oncogene Proteins
- Proto-Oncogene Proteins, met
- met Proto Oncogene Proteins
- Scatter Factor Receptor
- Receptor, HGF
- HGF Receptor
- Hepatocyte Growth Factor Receptor
- c-met Proteins
- c met Proteins
- MET Proto-Oncogene, Receptor Tyrosine Kinase
- MET Proto Oncogene, Receptor Tyrosine Kinase
- Receptor, Scatter Factor
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-met".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-met".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-met" by people in this website by year, and whether "Proto-Oncogene Proteins c-met" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 13 | 6 | 19 |
| 2018 | 3 | 2 | 5 |
| 2019 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-met" by people in Profiles.
-
Can COVID-19 induce glioma tumorogenesis through binding cell receptors? Med Hypotheses. 2020 Nov; 144:110009.
-
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clin Cancer Res. 2019 12 15; 25(24):7312-7319.
-
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clin Cancer Res. 2019 09 01; 25(17):5202-5211.
-
A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019 Mar 18; 38(1):130.
-
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. Clin Colorectal Cancer. 2019 06; 18(2):125-132.e2.
-
Placental morphology, apoptosis, angiogenesis and epithelial mechanisms in early-onset preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2019 Mar; 234:200-206.
-
Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles. Chem Res Toxicol. 2018 11 19; 31(11):1213-1218.
-
A PRDX1-p38a heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas. Int J Cancer. 2018 09 01; 143(5):1176-1187.
-
Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018 04 05; 173(2):355-370.e14.
-
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018 05; 19(5):682-693.